ValuEngine lowered shares of PURE Bioscience (OTCMKTS:PURE) from a hold rating to a sell rating in a research note published on Tuesday morning.

Shares of PURE Bioscience (OTCMKTS:PURE) opened at 1.01 on Tuesday. PURE Bioscience has a 12-month low of $0.75 and a 12-month high of $1.36. The firm has a 50-day moving average of $1.15 and a 200-day moving average of $1.07. The company’s market cap is $63.33 million.

TRADEMARK VIOLATION NOTICE: “PURE Bioscience (PURE) Downgraded to “Sell” at ValuEngine” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at

About PURE Bioscience

PURE Bioscience, Inc is focused on developing and commercializing antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. The Company’s technology platform is based on stabilized ionic silver and its products contain silver dihydrogen citrate (SDC).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with's FREE daily email newsletter.